Replies to post #105 on SciClone Pharmaceuticals, Inc. (SCLN)

[surf1944]

6:01AM SciClone Pharma announces China Government-mandated ZADAXIN price reduction; anticipates minimal impact on revenue and margins (SCLN) 4.69 : Co announces that consistent with the China government's review of pharmaceutical prices once a product has been included into the Reimbursement Drug List, the retail list price, or hospital pharmacy level price, of ZADAXIN has been reduced by about 18% in China. Based on agreements with co's primary importers of ZADAXIN into China to share the price reduction, the actual impact on co's revenue and margins is anticipated to be significantly lower than the percentage reduction at the retail level, and is expected to be less than a 5% decrease, with the importation and distribution network taking the majority of the percentage decrease. As co's prior financial guidance for 2012 included an anticipated price reduction impact in the range of ~7-8%, the newly announced NDRC price and related agreements with importers will result in a more favorable outcome than previously anticipated. Co plans to address any impact of this less than 5% price decrease on the 2012 guidance when it announces third quarter 2012 financial results.